Exodus Point Capital Management, LP Atreca, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.88 - $1.22 $37,891 - $52,530	-43,058 Reduced 8.44%	466,828 $457,000
Q1 2023 May 11, 2023	BUY	$0.91 - $1.82 $362,285 - $724,571	398,116 Added 356.19%	509,886 $581,000
Q4 2022 Feb 13, 2023	BUY	$0.78 - $1.68 $87,180 - $187,773	111,770 New	111,770 $89,000
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $27,638 - $89,268	-17,167 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.87 - $6.29 $12,266 - $26,883	-4,274 Reduced 19.93%	17,167 $52,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $21,289 - $39,327	-4,336 Reduced 16.82%	21,441 $134,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $201,576 - $355,722	25,777 New	25,777 $220,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.